Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Novo Nordisk

Wegovy maker Novo Nordisk rebuked by watchdog over failure to disclose payments to UK health groups

Danish drug giant found to have failed to accurately report spending even after admitting to errors

The Guardian - UK

‘Skinny jabs’ are turning slimmers teetotal – and drinks companies are feeling the loss

As the public rejoice at shedding weight, the likes of Wegovy seem to be controlling other bad habits – in particular drinking to excess

The Guardian - UK

Novo Nordisk stock surges 7% on new weight-loss drug update

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Novo Nordisk Stock Surges On Weight Loss Drug Data and Analysts Say It's Still a Buy

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight loss drug. Here's what you need to know.

Kiplinger

Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play

GLP-1 drugs have been all the rage for weight loss, but GE Healthcare and Novo Nordisk are working on a non-invasive approach to controlling metabolic functions

MarketBeat

LVMH dethrones Novo Nordisk as Europe's most valuable company

Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

Fortune

Novo Nordisk CEO attends crisis talks with Danish PM amid Trump's Greenland threats

Bosses from Fortune 500 Europe companies including Novo Nordisk, Lego, and Carlsberg met with the PM as Trump ups his threats over Greenland.

Fortune

Read news from The Economist, FT, and more,
with one subscription

How we diagnose and define obesity is set to change – here’s why, and what it means for treatment

Obesity is linked to many common diseases, such as type 2 diabetes, heart disease, fatty liver disease and knee osteoarthritis.

The Conversation

Trump Wants Greenland. Why That Could Be Bad News for Novo Nordisk Stock.

The pharma giant’s stock has been under pressure since the Greenland issue has been in the spotlight.

Barchart

Trump's Greenland Purchase Could Impact Drug Prices For Americans

President-elect Trump's interest in buying Greenland from Denmark could affect drug prices in the US.

Top News

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Novo Nordisk faces stock market bloodbath after drug trial disappoints

Shares in Novo Nordisk plunged 20% on Friday.

International Business Times

Ozempic May Face Investigation Over Vision-Threatening Condition In Some Patients

Danish health authorities asked the European Union to review two studies linking Novo Nordisk's diabetes drug, Ozempic, to a rare eye condition.

MarketBeat

Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

Fortune

Is Zepbound or Wegovy better for weight loss? New clinical trial reveals which medication sheds more pounds

Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Weight-loss meds go head-to-head in new study. One was significantly more effective, drugmaker says

In the first head-to-head test, people using Eli Lilly’s Zepbound lost just over 50 pounds while those using competitor Novo Nordisk’s Wegovy shed more than 33 pounds

The Conversation

Five things you should know about the HIV epidemic

It is 40 years since Aids was first identified. Major strides have been made since the spread of the virus reached epidemic proportions in 1995 when 3.3 million people were infected with HIV and just under one million people died.

Benzinga

What the Options Market Tells Us About Novo Nordisk

Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 14 unusual trades.

Kiplinger

Stock Market Today: The S&P 500 Reclaims the 6K Level

Investors see Scott Bessent as a safe shepherd of the economy as the president-elect burnishes his "Tariff Man" reputation.

Benzinga

Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs

The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis.

Fortune

Novo Nordisk Foundation CEO dismisses ‘Nokia risk’ to Denmark’s economy

Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion people living with obesity.

Salon

Wegovy on sale in China, cheaper than US

The medication is currently available in 16 other countries

1 … 15 16 17 18

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.